T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...

NOTCH1 pathway activation contributes to the pathogenesis of over 60% of T-cell acute lymphoblastic leukemia (T-ALL). While Notch is thought to exert the majority of its effects through ...

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene ...

Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.

Seven-year-old WA boy Ace was diagnosed with Acute Lymphoblastic Leukemia when he was just five years old. Acute lymphoblastic leukemia (ALL) is a type of blood cancer that occurs when the bone marrow ...

The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.

University of Illinois Chicago scientists have redesigned a treatment for the most common pediatric leukemia to eliminate its ...

Barrett told his grandma Honey, also known as Jill Lee, about the idea.

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK ...